Gerresheimer Expands Digital Healthcare Portfolio with Integrated Smart Injection Monitoring and Patient Engagement Platform

Gx InMonit – the smart autoinjector add-on with AI-based adherence support via the Gx AdheraLink platform.

(IN BRIEF) Gerresheimer has launched Gx InMonit, a smart add-on device for autoinjectors, along with Gx AdheraLink, an AI-driven messaging solution, to improve patient adherence to home-based injection therapies. The system guides patients through the injection process, captures real-time data, and transmits it automatically to the cloud without requiring additional apps or manual input. Combined with AI-powered reminders and patient interaction via familiar messaging platforms, the solution offers a more personalised and user-friendly approach to treatment management. By integrating device data with patient feedback, the ecosystem enables better monitoring of therapy adherence and supports improved health outcomes, addressing a significant global challenge in patient compliance.

(PRESS RELEASE) DUESSELDORF, 17-Mar-2026 — /EuropaWire/ — Gerresheimer has introduced Gx InMonit, a new smart add-on device designed to support patients administering self-injection therapies at home, alongside Gx AdheraLink, an AI-powered messaging solution aimed at improving treatment adherence. Together, the two technologies form a connected ecosystem that helps guide patients through treatment, capture real-world data, and enhance overall therapy outcomes.

Gx InMonit is designed to be mounted onto autoinjectors such as the Gx Inbeneo platform and provides step-by-step guidance throughout the injection process. Using a high-contrast AMOLED display combined with audible cues, the device assists patients from preparation through to completion, helping ensure that injections are performed correctly and in line with prescribed regimens. Built-in motion sensors detect key events such as injection start and completion, as well as potential errors like premature removal or failed administration.

The device also integrates temperature monitoring and near-field communication (NFC) capabilities to verify the drug, dosage, and device before use. Once the injection is completed, Gx InMonit automatically captures and transmits data via a cellular connection to the cloud, eliminating the need for manual input, app installation, or device pairing. This enables pharmaceutical companies and healthcare providers to access accurate, objective adherence data directly at the point of administration.

Complementing the device, Gx AdheraLink offers an AI-driven communication layer that interacts with patients through familiar messaging platforms such as WhatsApp or iMessage. The system delivers timely reminders ahead of scheduled injections, helping patients prepare and establish consistent routines. After administration, it provides encouraging feedback and allows users to share details about their experience, including pain levels and injection sites, which can be communicated to healthcare teams.

By combining device-generated data with patient-reported feedback, the integrated solution enables a more personalised approach to treatment support. The system continuously analyses behavioural patterns to refine engagement strategies, helping to improve adherence and deliver better health outcomes over time.

Gerresheimer highlights that adherence to prescribed therapies remains a major challenge, with global studies indicating that only around half of patients in developed countries follow treatment plans as directed. Solutions such as Gx InMonit and Gx AdheraLink are designed to address this gap by simplifying the treatment process, reducing patient anxiety, and improving engagement.

The new ecosystem builds on Gerresheimer’s broader digital health portfolio, complementing existing solutions such as Gx Cap, which is used in the United States to support adherence monitoring for oral medications through remote care services provided by Centor in collaboration with RxCap.

To find out more about Gx InMonit and Gx Adhera Link, please visit our website: Gx InMonit.

About Gerresheimer  
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, on-body devices, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production facilities in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,600 people. Gerresheimer AG is listed in the SDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). 

Media Contacts:

Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264
jutta.lorberg@gerresheimer.com

Dersim Korkmaz
Corporate Communication
T +49 211 6181 296

SOURCE: Gerresheimer